Literature DB >> 15115181

Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A.

M Zouhair Atassi1, Behzod Z Dolimbek.   

Abstract

Previously, we mapped the antibody (Ab) and T-cell recognition regions on the HC domain (residues 855-1296) of the 848-residue heavy (H) chain of botulinum neurotoxin A (BoNT/A). We have mapped here the HN-domain (residues 449-859) regions that bind protective anti-BoNT/A Abs raised in four different species. We synthesized, purified, and characterized 29 19-residue peptides that spanned the entire HN and overlapped consecutively by 5 residues, and also region L218-231 around the L-chain's substrate-binding site. Human, horse, mouse, and chicken anti-BoNT/A Abs did not bind to the L-peptide but recognized similar HN regions within peptides 519-537/533-551/547-565/561-579 (with slight left- or right-shifts), 743-761, 785-803, and 813-831/827-845 overlap. Recognition of other peptides that bound lower Ab levels showed similarities and also some differences. Peptide 463-481, strongly immunodominant with horse antisera, did not bind human, mouse, and chicken Abs. However, peptide 449-467 bound Abs in these three antisera, and the region may have shifted to the right (peptide 463-481) with horse Abs. The overlap 659-677/673-691 reacted strongly with human Abs whereas with mouse and chicken antisera, only peptide 673-691 showed low reactivity. Horse antisera had no detectable Ab binding to region(s) 659-691. The Ab-recognition regions on the H chain occupy surface locations in BoNT/A three-dimensional structure, but the great part of the surface is not immunogenic. Regions recognized by the protective antisera of the four different species are prime candidates for inclusion in synthetic vaccine designs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115181     DOI: 10.1023/b:jopc.0000016257.91979.06

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   4.000


  64 in total

1.  Protection against alpha-bungarotoxin poisoning by immunization with synthetic toxin peptides.

Authors:  B Z Dolimbek; M Z Atassi
Journal:  Mol Immunol       Date:  1996 May-Jun       Impact factor: 4.407

2.  Role of zinc in the structure and toxic activity of botulinum neurotoxin.

Authors:  F N Fu; R B Lomneth; S Cai; B R Singh
Journal:  Biochemistry       Date:  1998-04-14       Impact factor: 3.162

3.  Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.

Authors:  M Z Atassi; B Z Dolimbek; M Hayakari; J L Middlebrook; B Whitney; M Oshima
Journal:  J Protein Chem       Date:  1996-10

Review 4.  Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking of protein binding sites.

Authors:  M Z Atassi
Journal:  Eur J Biochem       Date:  1984-11-15

5.  Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice.

Authors:  L A Woodward; H Arimitsu; R Hirst; K Oguma
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

6.  Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.

Authors:  P Amersdorfer; C Wong; S Chen; T Smith; S Deshpande; R Sheridan; R Finnern; J D Marks
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

7.  Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor.

Authors:  M Z Atassi; T Manshouri; S Sakata
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

8.  Botulinal neurotoxin C1 complex genes, clostridial neurotoxin homology and genetic transfer in Clostridium botulinum.

Authors:  D Hauser; M Gibert; J C Marvaud; M W Eklund; M R Popoff
Journal:  Toxicon       Date:  1995-04       Impact factor: 3.033

9.  Nucleotide sequence of the gene coding for Clostridium botulinum (Clostridium argentinense) type G neurotoxin: genealogical comparison with other clostridial neurotoxins.

Authors:  K Campbell; M D Collins; A K East
Journal:  Biochim Biophys Acta       Date:  1993-12-14

Review 10.  Molecular aspects of tetanus and botulinum neurotoxin poisoning.

Authors:  G Ahnert-Hilger; H Bigalke
Journal:  Prog Neurobiol       Date:  1995-05       Impact factor: 11.685

View more
  16 in total

1.  Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.

Authors:  Cindi R Corbett; Erin Ballegeer; Kelly A Weedmark; M D Elias; Fetweh H Al-Saleem; Denise M Ancharski; Lance L Simpson; Jody D Berry
Journal:  Hybridoma (Larchmt)       Date:  2011-12

2.  Purification, modeling, and analysis of botulinum neurotoxin subtype A5 (BoNT/A5) from Clostridium botulinum strain A661222.

Authors:  Mark J Jacobson; Guangyun Lin; William Tepp; Jerome Dupuy; Pål Stenmark; Raymond C Stevens; Eric A Johnson
Journal:  Appl Environ Microbiol       Date:  2011-04-22       Impact factor: 4.792

3.  The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.

Authors:  B Vijayalakshmi Ayyar; K Roger Aoki; M Zouhair Atassi
Journal:  Infect Immun       Date:  2015-01-26       Impact factor: 3.441

Review 4.  Protein Structure Facilitates High-Resolution Immunological Mapping.

Authors:  Madison Zuverink; Joseph T Barbieri
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

5.  Inhibition of botulinum neurotoxin a toxic action in vivo by synthetic synaptosome- and blocking antibody-binding regions.

Authors:  M Zouhair Atassi; Behzod Z Dolimbek; Lance E Steward; K Roger Aoki
Journal:  Protein J       Date:  2010-07       Impact factor: 2.371

6.  Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.

Authors:  Wenhai Liu; Masanori Onda; Byungkook Lee; Robert J Kreitman; Raffit Hassan; Laiman Xiang; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

Review 7.  Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.

Authors:  Satoshi Nagata; Ira Pastan
Journal:  Adv Drug Deliv Rev       Date:  2009-08-11       Impact factor: 15.470

Review 8.  Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum.

Authors:  Laura M Zarebski; Kerrie Vaughan; John Sidney; Bjoern Peters; Howard Grey; Kim D Janda; Arturo Casadevall; Alessandro Sette
Journal:  Expert Rev Vaccines       Date:  2008-02       Impact factor: 5.217

9.  Novel neutralizing human monoclonal antibodies against tetanus neurotoxin.

Authors:  Takeharu Minamitani; Karin Kiyose; Ryota Otsubo; Toshihiro Ito; Hiroki Akiba; Rika A Furuta; Tsuyoshi Inoue; Kouhei Tsumoto; Masahiro Satake; Teruhito Yasui
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

Review 10.  Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.

Authors:  Sheng Chen
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.